Leitlinien sollen individuelle therapeutische Entscheidungen führen, aber nicht behindern. Immer muss für den Einzelfall abgewogen werden, ob möglicherweise aus guten Gründen eine Behandlung entgegen der Leitlinenempfehlungen erfolgen soll.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore). 1987;66(2):98–113.
Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6(6):530–9.
Mancuso M et al. Basal cell carcinoma and its development: insights from radiation-induced tumors in Ptch1-deficient mice. Cancer Res. 2004;64(3):934–41.
Kimonis VE et al. Clinical manifestations in 105 persons with nervoid basal cell carcinoma snydrome. Am J Med Genet. 1997;69(3):299–308.
Zagrodnik B et al. Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2. Cancer. 2003;98(12):2708–14.
Hassanpour SE et al. Basal cell carcinoma of scalp in patients with history of childhood therapeutic radiation: a retrospective study and comparison to nonirradiated patients. Ann Plast Surg. 2006;57(5):509–12.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zimmermann, F. Individuelle therapeutische Entscheidung oder Leitlinientreue?. Info Onkol. 18, 48–49 (2015). https://doi.org/10.1007/s15004-015-0999-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-015-0999-y